Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To present our proof of concept with semi-automatic image recognition/segmentation technology for calculation of tumour/parenchyma volume.

Methods: We reviewed Wilms' tumours (WTs) between 2000 and 2018, capturing computed tomography images at baseline, after neoadjuvant chemotherapy (NaC) and postoperatively. Images were uploaded into MATLAB-3-D volumetric image processing software. The program was trained by two clinicians who supervised the demarcation of tumour and parenchyma, followed by automatic recognition and delineation of tumour margins on serial imaging, and differentiation from uninvolved renal parenchyma. Volume was automatically calculated for both.

Results: During the study period, 98 patients were identified. Of these, based on image quality and availability, 32 (38 affected moieties) were selected. Most patients (65%) were girls, diagnosed at age 50 ± 37 months of age. NaC was employed in 64% of patients. Surgical management included 27 radical and 11 partial nephrectomies. Automated volume assessment demonstrated objective response to NaC for unilateral and bilateral tumours (68 ± 20% and 53 ± 39%, respectively), as well as preservation on uninvolved parenchyma with partial nephrectomy (70 ± 46 cm at presentation to 57 ± 41 cm post-surgery).

Conclusion: Volumetric analysis is feasible and allows objective assessment of tumour and parenchyma volume in response to chemotherapy and surgery. Our data show changes after therapy that may be otherwise difficult to quantify. Use of such technology may improve surgical planning and quantification of response to treatment, as well as serving as a tool to predict renal reserve and long-term changes in renal function.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.15026DOI Listing

Publication Analysis

Top Keywords

wilms' tumours
8
response chemotherapy
8
chemotherapy surgery
8
tumour parenchyma
8
parenchyma volume
8
parenchyma
5
volumetric assessment
4
assessment unaffected
4
unaffected parenchyma
4
parenchyma wilms'
4

Similar Publications

Chronic myeloid leukemia (CML), a myeloproliferative neoplasm, is characterized by the fusion gene, which results in constitutive tyrosine kinase activity. While tyrosine kinase inhibitors (TKIs) have significantly improved CML outcomes, resistance and the persistence of leukemic stem cells remain major clinical challenges. Curcumin, a natural polyphenol derived from , has demonstrated potential anticancer properties.

View Article and Find Full Text PDF

Diabetic nephropathy (DN) is a major cause of end-stage renal disease, with podocyte injury representing an early pathogenic event. Conventional biomarkers such as albuminuria and eGFR identify renal damage only at advanced stages, limiting opportunities for timely intervention. Wilms' Tumor 1 (WT1), a podocyte-specific transcription factor, has emerged as a sensitive marker of early glomerular stress.

View Article and Find Full Text PDF

Diabetic nephropathy (DN) is a major complication of diabetes, imposing substantial socioeconomic and public health challenges. N6-methyladenosine (m6A) modification, a prevalent epigenetic mechanism, influences cellular processes and disease progression. Wilms' tumor 1-associating protein (WTAP), an m6A methyltransferase subunit, was investigated for its role in DN.

View Article and Find Full Text PDF

Reconciling oncologic outcomes with renal preservation in Denys-Drash syndrome and recurrent Wilms Tumor. A case-based discussion.

Urology

September 2025

Atrium Health Carolinas Medical Center, Department of Urology, 1225 Harding Place Charlotte Unit 3100, NC 28204; Atrium Health Levine Children's Hospital, 1001 Blythe Blvd Suite 4100a Charlotte, NC 28204.

Denys Drash syndrome (DDS) results from a mutation in the WT1 tumor suppressor gene manifesting early in childhood. The classic presentation is characterized by early end stage renal disease (ESRD), differences of sexual differentiation (DSD), and high risk of Wilms tumor (WT). Management varies based on individual patient presentations.

View Article and Find Full Text PDF